TAC Versus TC for Adjuvant Breast Cancer

This study is ongoing, but not recruiting participants.
Information provided by:
US Oncology Research
ClinicalTrials.gov Identifier:
First received: June 27, 2007
Last updated: June 25, 2009
Last verified: June 2009

The purpose of this research study is to find out what effects (good and bad) TC or TAC has on you and your early stage HER2- breast cancer.

Condition Intervention Phase
Breast Cancer
Drug: Taxotere
Drug: Adriamycin
Drug: Cytoxan
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients

Resource links provided by NLM:

Further study details as provided by US Oncology Research:

Primary Outcome Measures:
  • to compare the 3-year DFS of adjuvant TC versus TAC as treatment for early stage HER2-negative breast cancer. [ Time Frame: 3-year ] [ Designated as safety issue: No ]

Estimated Enrollment: 2000
Study Start Date: May 2007
Estimated Study Completion Date: May 2015
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Taxotere
    Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
    Other Name: Docetaxel
    Drug: Adriamycin
    • Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
    Other Name: Doxorubicin
    Drug: Cytoxan
    600 mg/m2 IV over 15-30 minutes on Day 1.
    Other Name: Cyclophosphamide

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

A woman will be eligible for inclusion in this study if she meets all of the following criteria:

  • Age >18 to <70 years old.
  • Has known ER and PR status
  • Has HER2 nonamplified disease, confirmed by FISH
  • Has known menopausal status (see Section 7.3 for criteria)
  • Has operable, histologically confirmed, Stage I, IIA, IIB, or IIIA, IIIB, or IIIC invasive carcinoma of the breast. Bilateral synchronous breast cancer is allowable provided that 1 primary meets the inclusion criteria.
  • Meets 1 of the 3 following criteria:

    • T1-3N1-3M0 if ER positive or negative
    • T2-3N0M0 if ER positive or negative
    • T1N0M0 if ER and PR negative
  • Has complete surgical resection of the primary breast tumor: either lumpectomy or mastectomy with sentinel lymph node biopsy or axillary dissection, with clear margins for both invasive and ductal carcinoma in situ (DCIS)
  • Has had no prior chemotherapy unless >5 years ago
  • Has an ECOG Performance Status (PS) 0-1
  • Has laboratory values of: See protocol for specific details
  • Has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and alkaline phosphatase (ALP) within the ranges shown below. In determining eligibility the more abnormal of the 2 values (AST or ALT) should be used. See protocol for specific details
  • Has normal cardiac function as evidenced by a LVEF >50%, but WNL by institutional standard by multiple gated acquisition (MUGA) scan. An echocardiogram (ECHO) may be used if MUGA is not available, but the same modality must be used consistently throughout the study to evaluate LVEF. Ejection fraction as determined by ECHO must be WNL by institutional standard.
  • Has no evidence of metastatic disease outside of breast by physical examination and chest x-ray. Other scans if done as needed by the patient (eg, bone scan; abdominal, chest CT; PET or PET/CT; ultrasound; or MRI should indicate no evidence of metastatic disease
  • Has had baseline bilateral mammography
  • It has been <84 days since the date of definitive surgery (eg, mastectomy or, in the case of a breast-sparing procedure, axillary dissection) with adequate wound healing, as determined by the Treating Physician
  • Has a negative serum pregnancy test within 7 calendar days prior to registration (female patients of childbearing potential [not surgically sterilized and between menarche and 1 year postmenopause])
  • If fertile, patient has agreed to use an acceptable method of birth control (barrier contraceptive only) to avoid pregnancy for the duration of the study and for a period of 3 months thereafter
  • Has adequate tumor specimen available for FISH analysis of TOP2A status (See Appendix VI).
  • Has signed a Patient Informed Consent Form
  • Has signed a Patient Authorization Form

Exclusion Criteria:

A woman will be excluded from this study if she meets any of the following criteria:

  • Has any evidence of metastatic disease following surgical resection of the primary tumor including: positive surgical margins, staging work-up, or physical examination suspicious for malignant disease
  • Has T4 disease (ie, patients with fixed tumors, peau d'orange skin changes, skin ulcerations, or inflammatory changes)
  • Has Stage IV breast cancer (M1 disease on TNM staging system)
  • Has a history of severe hypersensitivity reaction to drugs formulated with polysorbate 80
  • Has had neoadjuvant chemotherapy for this breast cancer
  • Has ever had a myocardial infarction (MI) or has a history of heart failure, uncontrolled angina, severe uncontrolled arrhythmias, pericardial disease, or electrocardiographic evidence of acute ischemic changes
  • Is receiving concurrent immunotherapy, hormonal therapy (eg, tamoxifen, hormone replacement therapy), or radiation therapy. Must discontinue prior to registering on the study.
  • Is receiving concurrent investigational therapy or has received such therapy within the past 30 calendar days
  • Has peripheral neuropathy >Grade 1
  • Has had a major organ allograft or condition requiring chronic immunosuppression (ie, kidney, liver, lung, heart, bone marrow transplant, or autoimmune diseases). Patients who have received corneal transplants or cadaver skin or bone transplants are eligible.
  • Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious viral (including clinically defined AIDS), bacterial or fungal infection; or history of uncontrolled seizures, or diabetes, or CNS disorders deemed by the Treating Physician to be clinically significant, precluding informed consent
  • Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is known to be HIV positive
  • Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin, carcinoma in situ of uterine cervix, DCIS, which could affect the diagnosis or assessment of any of the study drugs
  • In an obese patient to whom the Treating Physician would not be comfortable administering full doses of study drugs as calculated by the BSA. Obese patients will be treated based on actual body weight. Obese patients treated with full doses based on actual BSA are eligible.
  • Is pregnant or breastfeeding
  • Is deemed unable to comply with requirements of study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00493870

  Show 95 Study Locations
Sponsors and Collaborators
US Oncology Research
Principal Investigator: Joanne L Blum, MD US Oncology Research
  More Information

No publications provided

Responsible Party: Regulatory Manager, US Oncology Research, Inc.
ClinicalTrials.gov Identifier: NCT00493870     History of Changes
Other Study ID Numbers: 11271
Study First Received: June 27, 2007
Last Updated: June 25, 2009
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antibiotics, Antineoplastic

ClinicalTrials.gov processed this record on April 17, 2014